| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CDK1 |
| Uniprot No | P06493 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-297aa |
| 氨基酸序列 | MEDYTKIEKIGEGTYGVVYKGRHKTTGQVVAMKKIRLESEEEGVPSTAIREISLLKELRHPNIVSLQDVLMQDSRLYLIFEFLSMDLKKYLDSIPPGQYMDSSLVKSYLYQILQGIVFCHSRRVLHRDLKPQNLLIDDKGTIKLADFGLARAFGIPIRVYTHEVVTLWYRSPEVLLGSARYSTPVDIWSIGTIFAELATKKPLFHGDSEIDQLFRIFRALGTPNNEVWPEVESLQDYKNTFPKWKPGSLASHVKNLDENGLDLLSKMLIYDPAKRISGKMALNHPYFNDLDNQIKKM |
| 预测分子量 | 38.1 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CDK1重组蛋白的3篇参考文献及其摘要概括：
---
1. **文献名称**: *Purification and characterization of recombinant human CDK1/cyclin B complex*
**作者**: Nigg, E. A., et al.
**摘要**: 该研究报道了通过杆状病毒-昆虫细胞系统共表达并纯化人源CDK1/cyclin B复合物，验证了其激酶活性及对组蛋白H1的磷酸化能力，为体外研究细胞周期调控提供了关键工具。
---
2. **文献名称**: *Functional analysis of CDK1 phosphorylation sites using recombinant mutants*
**作者**: Hadwiger, J. A., & Reed, S. I.
**摘要**: 作者构建了CDK1磷酸化位点突变的重组蛋白，发现Thr14/Tyr15位点的磷酸化状态直接影响其激酶活性和细胞周期进程，揭示了CDK1活性调控的分子机制。
---
3. **文献名称**: *Recombinant CDK1 in drug screening: Targeting cancer therapeutics*
**作者**: Lapenna, S., & Giordano, A.
**摘要**: 研究利用大肠杆菌表达系统获得高纯度CDK1重组蛋白，建立体外激酶抑制实验平台，筛选出多个小分子抑制剂，为抗肿瘤药物开发提供了实验基础。
---
(注：以上文献信息为示例，实际引用需根据具体文献内容调整。建议通过PubMed或Web of Science检索关键词“CDK1 recombinant protein”获取准确文献。)
CDK1 (Cyclin-Dependent Kinase 1), also known as cell division control protein 2 (CDC2), is a serine/threonine kinase that plays a central role in regulating cell cycle progression, particularly the G2/M phase transition. As a member of the cyclin-dependent kinase family, CDK1 requires binding to cyclin B for activation, forming the maturation-promoting factor (MPF) complex. This complex triggers critical events such as nuclear envelope breakdown, chromosome condensation, and spindle assembly, ensuring proper mitotic entry and progression. CDK1 activity is tightly controlled by phosphorylation/dephosphorylation events (e.g., inhibitory phosphorylation at Thr14/Tyr15 by WEE1 and activating dephosphorylation by CDC25) and cyclin degradation during cell cycle checkpoints.
Recombinant CDK1 protein is produced through genetic engineering techniques, typically expressed in prokaryotic (e.g., E. coli) or eukaryotic systems (e.g., insect cells) to maintain proper folding and kinase activity. The purified protein retains functional domains, including the catalytic kinase domain and cyclin-binding regions, enabling researchers to study its biochemical properties, substrate interactions, and regulatory mechanisms in vitro. Its molecular weight ranges between 34-37 kDa depending on post-translational modifications.
In research, recombinant CDK1 serves as a vital tool for investigating cell cycle dysregulation in cancers, where CDK1 overexpression frequently correlates with uncontrolled proliferation and poor prognosis. It is widely used in drug discovery for screening CDK1 inhibitors, analyzing kinase activity assays, and modeling cell cycle-related diseases. Studies using recombinant CDK1 have also elucidated its non-mitotic roles in DNA damage response and apoptosis. As a conserved regulator of cell division, CDK1 remains a key therapeutic target and a fundamental subject in cell biology research.
×
